Medication Treatment for Opioid Use Disorder in Expectant Mothers: infant Neurodevelopmental Outcomes Sub-study

This is a sub‐study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019‐0429‐1). Caretakers of the infants delivered by MOMs participants will be offered the opportunity to enroll in this sub‐study, which is designed to evaluate the impact of extended‐release buprenorphine (BUP‐XR), relative to sublingual buprenorphine (BUP‐SL), on infant neurodevelopment. The additional data collected in this sub‐study will be combined with data from the main MOMs trial.